Clinical translation of folate receptor-targeted therapeutics

Bibliography

• Bailey LB, Gregory JF. Folate metabolism and requirements. J Nutr 1999;129:779-82
   PubMed Web of Science ®Google Scholar
• Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-84
   PubMed Web of Science ®Google Scholar
• Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111-28
   PubMed Web of Science ®Google Scholar
• Garrow TA, Admon A, Shane B. Expression cloning of a human cDNA encoding folylpoly(gamma-glutamate) synthetase and determination of its primary structure. Proc Natl Acad Sci USA 1992;89:9151-5
   PubMed Web of Science ®Google Scholar
• Kamen BA, Smith AK. A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv Drug Deliv Rev 2004;56:1085-97
   PubMed Web of Science ®Google Scholar
• Weitman SD, Lark RH, Coney LR, Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401
   PubMed Web of Science ®Google Scholar
• Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptor. Expert Opin Drug Deliv 2008;5:309-19
   PubMed Web of Science ®Google Scholar
• Low PS, Kularantne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62
   PubMed Web of Science ®Google Scholar
• Salazar MD, Ratnam M. The folate receptor:what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev 2007;26:141-52
   PubMed Web of Science ®Google Scholar
• Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem 2010;53:6811-24
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cernigoi C, Russo A, Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Westrick E, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93
   PubMed Web of Science ®Google Scholar
• Jones MB, Neuper C, Clayton A, Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas. Int J Cancer 2008;123:1699-703
   PubMed Web of Science ®Google Scholar
• Nunez MI, Behrens C, Woods DM, High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR Mutation. Lab Invest 2011;91:420A-1A
   Web of Science ®Google Scholar
• Franklin WA, Waintrub M, Edwards D, New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J cancer Suppl 1994;8:89-95
   PubMedGoogle Scholar
• Nitzkorski JR, Paty PB, Klimstra DS, Patterns of immunohistochemical expression of folate receptor alpha (FRa) in colorectal epithelium and its neoplasms. Mod Pathol 2007;20:124A-A
   Web of Science ®Google Scholar
• Bueno R, Appasani K, Mercer H, The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121:225-33
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Keeney GL, Lingle WL, Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007;121:938-42
   PubMed Web of Science ®Google Scholar
• Kalli KR, Obert AL, Keeney GL, Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108:619-26
   PubMed Web of Science ®Google Scholar
• Brown Jones M, Neuper C, Clayton A, Rationale for folate receptor alpha targeted therapy in “high risk” endometrial carcinomas. Int J Cancer 2008;123:1699-703
   PubMed Web of Science ®Google Scholar
• Iwakiri S, Sonobe M, Nagai S, Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008;15:889-99
   PubMed Web of Science ®Google Scholar
• O'Shannessy DJ, Yu G, Smale R, Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012;3:414-25
   PubMed Web of Science ®Google Scholar
• Ross JF, Wang H, Behm FG, Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 1999;85:348-57
   PubMed Web of Science ®Google Scholar
• Puig-Kroger A, Ratnam M, Sanchez-Mateos P, Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res 2009;69:9395-403
   PubMed Web of Science ®Google Scholar
• van der Heijden JW, Oerlemans R, Dijkmans BA, Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 2009;60:12-21
   PubMed Web of Science ®Google Scholar
• Paulos CM, Turk MJ, Breur GJ, Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 2004;56:1205-17
   PubMed Web of Science ®Google Scholar
• Leamon CP, Jackman AL. Exploitation of the folate receptor in the management of cancer and inflammatory disease. Vitam Horm 2008;79:203-33
   PubMed Web of Science ®Google Scholar
• Pan XQ, Zheng X, Shi G, Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 2002;100:594-602
   PubMed Web of Science ®Google Scholar
• Miotti S, Canevari S, Menard S, Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal-antibodies with tumor-restricted specificity. Int J Cancer 1987;39:297-303
   PubMed Web of Science ®Google Scholar
• Molthoff CF, Buist MR, Kenemans P, Experimental and clinical analysis of the characteristics of a chimeric monoclonal-antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 1992;33:2000-5
   PubMed Web of Science ®Google Scholar
• Buist MR, Kenemans P, Denhollander W, Kinetics and tissue distribution of the radiolabeled chimeric monoclonal-antibody MOv18 IgG and F(ab')(2) fragments in ovarian-carcinoma patients. Cancer Res 1993;53:5413-18
   PubMed Web of Science ®Google Scholar
• Tibben JG, Boerman OC, Massuger L, Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')(2) in ovarian carcinoma patients. Int J Cancer 1996;66:477-83
   PubMed Web of Science ®Google Scholar
• Miotti S, Negri DR, Valota O, Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 1999;84:62-8
   PubMed Web of Science ®Google Scholar
• Crippa F, Bolis G, Seregni E, Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal-antibody I-131 MOv18 - clinical-results in patients with minimal residual disease of ovarian-cancer. Eur J Cancer 1995;31A:686-90
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16:5288-95
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;10:431-7
   PubMed Web of Science ®Google Scholar
• Kalli KR. Drug evaluation: MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. Curr Opin Investig Drug 2007;8:1067-73
   PubMed Web of Science ®Google Scholar
• Garin-Chesa P, Campbell I, Saigo PE, Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993;142:557-67
   PubMed Web of Science ®Google Scholar
• Smith-Jones PM, Pandit-Taskar N, Cao W, Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008;35:343-51
   PubMed Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM. Sabbatini P, et al. arletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010;16:5288-95
   PubMed Web of Science ®Google Scholar
• Armstrong D. Farletuzumab (MORAb-003) in platinum-sensitive ovarian cancer patients experiencing a first relapse. Commun Oncol 2010;7(Suppl 1):1-4
   Google Scholar
• Markman M, Markman J, Webster K, Duration of response to second-line, platinum based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004;22:3120-312
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK, Weil S, Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). J Clin Oncol 2011;29(Suppl):abstract 5056
   Google Scholar
• Toi M, Sperinde J, Huang W, Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer 2010;10:56
   PubMed Web of Science ®Google Scholar
• Guo W, Hinkle GH, Lee RJ. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999;40:1563-9
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198-204
   PubMed Web of Science ®Google Scholar
• Park EK, Kim SY, Lee SB, Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005;109:158-68
   PubMed Web of Science ®Google Scholar
• Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 1996;271:8481-7
   PubMed Web of Science ®Google Scholar
• Leamon CP, Pastan I, Low PS. Cytotoxicity of folate-pseudomonas exotoxin conjugates toward tumor cells. J Biol Chem 1993;268:24847-54
   PubMed Web of Science ®Google Scholar
• Li H, Lu Y, Piao L, Folate-immunoglobulin G as an anticancer therapeutic antibody. Bioconjug Chem 2010;21:961-8
   PubMed Web of Science ®Google Scholar
• Roy EJ, Cho BK, Rund LA, Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate. Int J Cancer 1998;76:761-6
   PubMed Web of Science ®Google Scholar
• Gawlick U, Kranz DM, Schepkin VD, A conjugate of a tumor-targeting ligand and a T cell costimulatory antibody to treat brain tumors. Bioconjug Chem 2004;15:1137-45
   PubMed Web of Science ®Google Scholar
• Mullen DG, McNerny DQ, Desai A, Design, synthesis, and biological functionality of a dendrimer-based modular drug delivery platform. Bioconjug Chem 2011;22:679-89
   PubMed Web of Science ®Google Scholar
• Lu JY, Lowe DA, Kennedy MD, Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Target 1999;7:43-53
   PubMed Web of Science ®Google Scholar
• Matteson EL, Lowe VJ, Prendergast FG, Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin Exp Rheumatol 2009;27:253-9
   PubMed Web of Science ®Google Scholar
• Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev 2004;56:1161-76
   PubMed Web of Science ®Google Scholar
• Vlahov IR, Santhapuram HK, Keindl PJ, Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006;16:5093-6
   PubMed Web of Science ®Google Scholar
• Siegel BA, Dehdashti F, Mutch DG, Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-7
   PubMed Web of Science ®Google Scholar
• Fisher RE, Siegel BA, Edell SL, Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008;49:899-906
   PubMed Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LM, Intraoperative tumor-specific fluorescence imaging in ovariancancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315-19
   PubMed Web of Science ®Google Scholar
• Reddy JA, Westrick E, Santhapuram HKR, Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 2007;67:6376-82
   PubMed Web of Science ®Google Scholar
• Vanderwilt CL, Pinedo HM, Dejong M, Effect of folate diastereoisomers on the binding of 5-fluoro-2′-deoxyuridine-5′-monophosphate to thymidylate synthase. Biochem Pharmacol 1993;45:1177-9
   PubMed Web of Science ®Google Scholar
• Aronov O, Horowitz AT, Gabizon A, Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug Chem 2003;14:563-74
   PubMed Web of Science ®Google Scholar
• Lee JW, Lu JY, Low PS, Fuchs PL. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorg Med Chem 2002;10:2397-414
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Dawson A. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol Pharm 2009;6:1518-25
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Westrick E, Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42
   PubMed Web of Science ®Google Scholar
• Li J, Klein P, Morgenstern D, Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate ec145 in cancer patients. Clin Pharmacol Ther 2009;85:S43-3
   Web of Science ®Google Scholar
• Pribble P, Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 2012;21:755-61
   PubMed Web of Science ®Google Scholar
• Naumann RW, Symanowski JT, Ghamande SA, Precedent: a randomized phase II trial comparing EC145 and pegylated lisosomal doxyrubicin (PLD) versus PLD alone, in subjects with platinum-resistant ovarian cancer. Am Soc Clin Oncol Ann Meet 2010;28:5012
   Google Scholar
• Leamon CP, Reddy JA, Klein PJ, Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J Pharmacol Exp Ther 2011;336:336-43
   PubMed Web of Science ®Google Scholar
• Amato RJ, Engel J, Lu P, Low F. Phase I trial of EC90 (keyhole-limpet hemocyanin fluorescein isothiocyanate conjugate) with GPI-0100 adjuvant followed by EC 17 (folate-fluorescein isothiocyanate conjugate) in patients with metastatic renal cell carcinoma and ovarian cancer. J Clin Oncol 2004;22(14S):4754
   Google Scholar
• Messmann R, Amato R, Hernandez-McClain J, A phase II study of FolateImmune (EC90 with GP1–0100 adjuvant followed by EC17) with low dose cytokines interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) in patients with refractory or metastatic cancer. J Clin Oncol 2007;25(18S):13516
   Google Scholar
• Ulrich CM, Potter JD. Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 2006;15:189-93
   PubMed Web of Science ®Google Scholar